MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.05
-0.47
-6.25%
After Hours: 7.05 0 0.00% 16:56 03/27 EDT
OPEN
7.27
PREV CLOSE
7.52
HIGH
7.58
LOW
7.03
VOLUME
1.59M
TURNOVER
--
52 WEEK HIGH
10.53
52 WEEK LOW
2.990
MARKET CAP
915.50M
P/E (TTM)
-2.9856
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AKBA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AKBA stock price target is 15.04 with a high estimate of 23.00 and a low estimate of 8.00.

EPS

AKBA News

More
  • Edited Transcript of AKBA earnings conference call or presentation 10-Mar-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference
  • PR Newswire · 4d ago
  • A Message from Akebia Therapeutics, Inc.s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:
  • Business Wire · 03/16 02:28
  • Akebia files to offer up to $65M in stock
  • seekingalpha · 03/13 04:03

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About AKBA

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
More

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.